This paper was translated from Chinese into English by Medical Translation and edited by Wei Liu. Received: 20100511; Accepted: 20100917 microRNA (miRNA) is a class of singlestrand noncoding RNA (2125 nucleotides). Studies have suggested that miRNAs control the expression of 1/3 of all human genes and are involved in a series of biological processes. miRNAs can function as oncogenes or tumor suppressor genes during tumorigenesis and cancer progression, and are thus closely related to cancer diagnosis, proliferation, metastasis, clinical stages and prognosis [1] . With the growing knowledge of the relation between miRNAs and cancer, it is also shown that the sensitivity of cancer cells to anticancer drug is affected by miRNAs [2] . miRNA200c is a member of miRNA200 family, which includes miRNA200a, miRNA200b, miRNA200c, miRNA141, and miRNA429. Previous studies showed that miRNA200c inhibits cancer epithelialtomesenchymal 窑Original Article窑 transition (EMT) and metastasis by negatively regulating zinc finger Ebox binding homeobox 1 (ZEB1) and indirectly upregulating Ecadrin [3, 4] . In addition, miRNA200c directly regulates the expression of TUBB3 and ERRFI1, which accounts for the increase of cancer cell sensitivity to paclitaxel and epidermal growth factor inhibitor, respectively [5, 6] . Besides the involvement of target genes of miRNA200c in the drugresistance of cancer cells, miRNA200c also increases the sensitivity of breast cancer MDAMB231 cells to adriamycin (ADR) [7] . After transfection with miRNA200c, cell proliferation is inhibited and the expressions of proapoptotic related genes are upregulated, whereas those of prosurvival genes are downregulated. However, the signaling pathways resulting in the increased drugsensitivity are not fully understood. Furthermore, miRNA expression profiling assay showed that miRNA200c is downregulated in some drugresistant cancer cell lines [8, 9] . Therefore, the mechanism of miRNA200c in cancer drugresistance needs further study.
After reviewing literatures, we found that Ecadherin, a downstream target protein of miRNA200c, is related to cancer drugresistance. This finding provides a theoretical basis for revealing the mechanism of reversing drugresistance by miRNA200c. Ecadherin belongs to the adhesion molecule family, which mediates homotypic cell adhesion and inhibits cancer cell metastasis. Recent studies demonstrated that the expression of Ecadherin in some drugresistant cancer cells is significantly downregulated or lost [10, 11] . Ecadherin not only functions as a metastasis inhibitor but also plays a role in the reversal of cancer drugresistance. Several studies showed that Ecadherin increases the sensitivity of cancer cells to cytotoxic drugs [such as methotrexate, etoposide, cisplatin (DDP), and so on] and epidermal growth factor inhibitor. Ecadherin negatively regulates Bcl2 expression and thus reverses the resistance to chemotherapeutic drugs [12] . Therefore, we hypothesize that the regulation of apoptotic proteins by Ecadherin is a key step in the multiple biological regulations by miRNA200c, and this subject needs to be further explored.
DDP, 5fluorouracil (5FU), paclitaxel, and ADR are major drugs currently used for gastric cancer chemotherapy. SGC7901 cells are originated from human gastric adenocarcinoma and are widely used in China for in vitro studies of gastric cancer. We have prepared a DDPresistant cell line SGC7901/DDP by intermittent induction. SGC7901/DDP cells can grow in mediums containing 1 ml/L DDP. In our previous study, we found that the expression level of miRNA200c is significantly lower in SGC7901/DDP cells than in SGC7901 cells [13] . Overexpression of miRNA200c not only upregulates the expression of Ecadherin but also increases the sensitivity of SGC7901/DDP cell to DDP. To further investigate the biological effects and molecular mechanisms of miRNA200c in SGC7901/DDP cells, we explored in the present study the function of miRNA200c in drugresistance and proliferation of SGC7901/DDP cells. Western blot was used to detect the protein expression of Ecadherin, Bax, and Bcl2 after miRNA200c transfection. In addition, we knocked down Ecadherin expression in SGC7901 cells using small interfering RNA (siRNA) and determined drugresistance and cell proliferation, as well as the expression levels of Bax and Bcl2. We aimed to delineate the function of Ecadherin in miRNA200c regulated sensitivity of cancer cell to anticancer drugs.
Fetal calf serum (FCS) and RPMI1640 medium were purchased from Gibco; Lipofectamine 2000 and Trizol were from Invitrogen; antibodies against Ecadherin, Bcl2, Bax, and 茁 actin were from Santa Cruz; IRDye Precursor sequence, and Negative Control #1 sequence were from Ambion; Ecadherin siRNA sequence and negative control sequence were synthesized by Shanghai GenePharma Co., Ltd. The Ecadherin siRNA sequence was 5'CAGACAAAGACCAGGACUA3'; The negative control sequence was 5'UUCUCCGAACGUGUCACGU TT 3'. Odyssey twocolor infrared imaging system was from LICOR Biosiences. Human DDPresistant and nonresistant gastric cancer lines (SGC9701/DDP and SGC9701) were stored in our lab. Cells were cultured in RPMI1640 medium containing 10% FCS at 37益 with 5% CO 2 . Drugresistant cells were cultured in the medium supplemented with 1 mg/L DDP. SGC7901/DDP cells in logarithmic growth phase were trypsinized with 0.25% trypsine, then suspended in RPMI1640 containing 10% FCS and seeded in 6well plates (3 伊 10 5 cells/well). Transfection of miRNA200c Precursor (Pre200c) and its negative control sequence were performed according to the manual provided with the siPOR TM NeoFX TM Transfection Agent. SGC7901 cells were seeded into 6well plates (4 伊 10 5 cells/well). After 24 h, Ecadherin siRNA and the negative control siRNA were transfected using Lipofectamine 2000. The transfected cells were used for cell proliferation, MTT drugsensitivity and Western blot experiments.
The total RNA was extracted from SGC7901/DDP cells at 24 h after transfection with Pre200c or the negative control sequence, followed by realtime RTPCR. Briefly, cDNA were synthesized using a miRNA200c specific primer in reverse transcription system. The reaction condition was as follows: 16益 30 min, 42益 42 min, 85益 5 min. Quantitative detection of RT products was performed using specific sense and antisense primers of miRNA200c and Sybergreen I dye. The PCR reaction condition was as follows: 95益 for 5 min; 40 cycles of 95益 for 10 s, 60益 for 20 s, 72益 for 20 s, and 78益 for 20 s to obtain fluorescence intensity. U6 was used as an internal control. The sequence of specific primer for miRNA200c was 5'GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAA TGCACTGGATACGACTCCATC3'; the sequence of sense primer of miRNA200c was 5'GGTAATACTGCCGGGTA AT3'; the sequence of antisense primer of miRNA200c was 5'CAGTGCGTGTCGTGGAGT3'. The data were analyzed using 2 △△Ct method:
At 24 h after transfection of Pre200c, SGC7901/DDP cells were trypsinized using 0.25% trypsin, then suspended in RPMI1640 medium containing 10% FCS and seeded in 96well plates (7 伊 10 3 cells in 100 滋 L medium/well). Upon attachment of the cells, different concentrations of DDP, 5FU, paclitaxel, and ADR were added in triplicate wells of the plates. Control wells and zero adjusted wells were also set. After 48 h, 20 滋 L fresh MTT reagent (5 滋 g/滋 L) was added into each well and the cells were cultured at 37益 in 5% CO 2 for another 4 h. The medium was discarded carefully and 150 滋 L DMSO was added and votexed for 10 min. Absorbance at 490 nm was measured in an ELISA reader. The mean absorbance of triplicate wells was set as value of each group. The cell inhibition rate of each drug group = ( value of control group value of drug group) / value of control group 伊 100%. The 50% inhibition concentration (IC 50 ) was calculated according to the cell inhibition curve.
At 24 h after transfection of Pre200c, SGC7901/DDP cells were trypsinized using 0.25% trypsin, then suspended in RPMI1640 medium containing 10% FCS and seeded in 24well plates (1 伊 10 4 cells/well). Cells were counted after trypsinization every day at the same time point. Each group contains triplicate wells. The growth curve was then drawn.
Cells were harvest and washed for 2 times 72 h after transfection of Pre200c. Cells were lysed using 100 滋 L lysis buffer at 4 益 for 30 min . The lysate was centrifuged for 10 min at 12 000 伊 . Protein assay was performed using Bradford method. Proteins (50 滋 g) were separated by electrophoresis in 12% SDSPAGE gel and then transferred onto a PVDF membrane. The membrane was blocked with 5% dry milk for 1 h, then incubated overnight with the primary antibody at 4益 . Subsequently, the membrane was incubated with the secondary antibody (1 : 10 000) for 1 h in dark. After extensive wash, the membrane was scanned using the Odyssey twocolor infrared imaging system. The value of optical density (OD) was calculated. Protein expression levels were defined as the OD of objective protein / the OD of 茁 actin.
All data are presented as mean 依 standard deviation. The test was performed to determine differences between groups using SPSS13.0 statistical software. < 0.05 was considered significant.
Realtime RTPCR showed that the △ Ct of miRNA200c in Pre200ctransfected SGC7901/DDP cells was 7.1 依 0.2 times of that in control cells (12.66 依 0.08 vs. 15.49 依 0.08, < 0.05).
The IC 50 of DDP, 5FU, paclitaxel, and ADR were (7.52 依 0.19) mg/L, (7.27 依 0.09) mg/L, (1.70 依 0.33) mg/L, and miRNAs, a class of 2125 nt singlestrand noncoding RNAs, negatively regulate the expression of other genes by interfering mRNA translation and are involved in multiple processes of tumorigenesis and cancer progression. miRNA200c belongs to the miRNA200 family. miRNA200c inhibits the EMT process of cells [3] , tumor invasion and metastasis [4] . In addition, miRNA200c also increases drug sensitivity of cancer cells to paclitaxel, epidermal growth factor inhibitors, and ADR [57] . After transfecting SGC7901/DDP cells with Pre200c, we found that the expression of miRNA200c was significantly increased as shown by realtime PCR analysis and the drug sensitivity of SGC7901/DDP cells to DDP, 5FU, paclitaxel, and ADR was significantly enhanced. Furthermore, significant growth inhibition was observed in the Pre200ctransfected SGC7901/DDP cells. Recent studies suggested that miRNA200c can regulate the expression of proliferation and apoptosisrelated genes [7] . Therefore, we hypothesized that the roles of miRNA200c in the inhibition of gastric cancer cell proliferation and the reverse of drug resistance are related with these genes. In this study, we found that Ecadherin expression was significantly enhanced in SGC7901/DDP cells after transfection of Pre200c, which was accompanied by the increase of Bax expression and the decrease of Bcl2 expression. Influencing the homeostasis of cell apoptosis might be one of the most important mechanisms by which miRNA200c induces the reversal of cancer cell drug resistance. However, the downstream genes of miRNA200c that regulate apoptosisrelated genes have not been reported.
Recent studies have shown that Ecadherin not only regulates cancer metastasis but also plays an important role in cancer drug resistance. Ecadherin reverses the resistance of cancer cells to chemotherapeutic drugs by negatively regulating the expression of Bcl 2 [12] . In addition, Ecadherin inhibits cell proliferation by regulating the expression of P27 [14] . Therefore, Ecadherin may play a key role in the miRNA200cinduced biological consequences. To further study the function of Ecadherin in the miRNA200c pathway, we specifically inhibited the expression of Ecadherin by siRNA in SGC7901 cells and found that the expression of Ecadherin was dramatically inhibited. At 72 h after siRNA transfection, the protein level of Bax was significantly lower than that in the control group, whereas the protein level of Bcl2 was significantly higher than that in the control group. Therefore, miRNA200c may regulate Bax and Bcl2 expression via Ecadherin. Whether miRNA200c inhibits cell proliferation via Ecadherin needs further study.
Understanding how Ecadherin regulates apoptosis and proliferationrelated genes will help to delineate the molecular mechanism of miRNA200c function. A recent study suggested that Ecadherin increases the expression of tumor suppressor gene PTEN [15] , a protein that is abnormally expressed in a variety of cancer cells. PTEN plays a role in cell proliferation, apoptosis, and chemotherapy resistance through the phosphatidylinositol3 kinase (PI3K)/Akt signaling pathway. PTEN can regulate apoptosisrelated genes (such as Bax and Bcl2) through inhibiting the PI3K/Akt signaling pathway [16, 17] and increases the sensitivity of cancer cells to various anticancer drugs (DDP, ADR and cetuximab), thus playing an important role in antitumor and the reversal of drug resistance [16, 1822] . In our previous study [13] , we found that miRNA200c increases PTEN protein expression in SGC7901/DDP cells, suggesting that Ecadherin may regulate proliferation and apoptosisrelated genes through PTEN. We are currently testing this hypothesis.
In summary, we speculate that miRNA200c indirectly regulates the expression of apoptosisrelated genes through Ecadherin. This pathway may serve as an important mechanism by which miRNA200c induces proliferation inhibition and the reversal of drug resistance. We will further explore how Ecadherin regulates downstream pathways that lead to cell proliferation and apoptosis. After E鄄 cadherin siRNA transfection, the protein level of Bax in SGC7901 cells was significantly decreased, whereas that of Bcl鄄 2 was increased.
